celecoxib has been researched along with Alloxan Diabetes in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Formalin (0." | 5.42 | Celecoxib reduces hyperalgesia and tactile allodynia in diabetic rats. ( Bermúdez-Ocaña, DY; Ble-Castillo, JL; Díaz-Zagoya, JC; Granados-Soto, V; Juárez-Rojop, IE; Morales-Hernández, PE; Torres-Lopez, JE; Tovilla-Zárate, CA, 2015) |
| "Formalin (0." | 1.42 | Celecoxib reduces hyperalgesia and tactile allodynia in diabetic rats. ( Bermúdez-Ocaña, DY; Ble-Castillo, JL; Díaz-Zagoya, JC; Granados-Soto, V; Juárez-Rojop, IE; Morales-Hernández, PE; Torres-Lopez, JE; Tovilla-Zárate, CA, 2015) |
| "Celecoxib treatment inhibited VEGF mRNA expression without any significant reduction in cyclooxygenase-2 mRNA." | 1.32 | Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. ( Ayalasomayajula, SP; Kompella, UB, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, Y | 1 |
| Gao, L | 1 |
| Juárez-Rojop, IE | 1 |
| Morales-Hernández, PE | 1 |
| Tovilla-Zárate, CA | 1 |
| Bermúdez-Ocaña, DY | 1 |
| Torres-Lopez, JE | 1 |
| Ble-Castillo, JL | 1 |
| Díaz-Zagoya, JC | 1 |
| Granados-Soto, V | 1 |
| Cheruvu, NP | 2 |
| Amrite, AC | 3 |
| Kompella, UB | 5 |
| Nasrallah, R | 1 |
| Robertson, SJ | 1 |
| Karsh, J | 1 |
| Hébert, RL | 1 |
| Ayalasomayajula, SP | 4 |
| Berkowitz, BA | 1 |
| Roberts, R | 1 |
| Luan, H | 1 |
| Peysakhov, J | 1 |
| Knoerzer, DL | 1 |
| Connor, JR | 1 |
| Hohman, TC | 1 |
9 other studies available for celecoxib and Alloxan Diabetes
| Article | Year |
|---|---|
Celecoxib Alleviates Memory Deficits by Downregulation of COX-2 Expression and Upregulation of the BDNF-TrkB Signaling Pathway in a Diabetic Rat Model.
Topics: Animals; Brain-Derived Neurotrophic Factor; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2017 |
Celecoxib reduces hyperalgesia and tactile allodynia in diabetic rats.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diabetes Mellitus, Experimental; Dose-Response Rela | 2015 |
Effect of diabetes on transscleral delivery of celecoxib.
Topics: Animals; Area Under Curve; Blood Glucose; Blood-Retinal Barrier; Body Weight; Capillary Permeability | 2009 |
Celecoxib modifies glomerular basement membrane, mesangium and podocytes in OVE26 mice, but ibuprofen is more detrimental.
Topics: Albumins; Animals; Blood Glucose; Blood Pressure; Celecoxib; Creatinine; Cyclin-Dependent Kinase Inh | 2013 |
Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model.
Topics: Animals; Blood Glucose; Body Weight; Capillary Permeability; Celecoxib; Cornea; Cyclooxygenase 2; Cy | 2003 |
Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase | 2004 |
Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model.
Topics: Aldehydes; Animals; Celecoxib; Conjunctiva; Cyclooxygenase Inhibitors; Delayed-Action Preparations; | 2005 |
Drug intervention can correct subnormal retinal oxygenation response in experimental diabetic retinopathy.
Topics: Animals; Blood Glucose; Carbon Dioxide; Celecoxib; Cyclooxygenase Inhibitors; Diabetes Mellitus, Exp | 2005 |
Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage.
Topics: Animals; Blood-Retinal Barrier; Capillary Permeability; Celecoxib; Cell Culture Techniques; Cyclooxy | 2006 |